CRVS
Corvus Pharmaceuticals, Inc.
Key Financials
Total Assets
$71.1M
↑ 3.2%
Shareholders' Equity
$61.2M
↑ 87.9%
Net Income
$-15283000
↑ 75.5%
Total Liabilities
$9.9M
↓ 72.7%
EPS (Diluted)
$-0.53
↑ 48.0%
Operating Income
$-42971000
↓ 56.0%
Cash & Equivalents
$4.6M
↓ 47.6%
Operating Cash Flow
$-32797000.00
↓ 29.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 8/7/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| SCHEDULE 13G/A | 7/27/2026 | View on SEC |
| 8-K | 7/22/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CRVS |
| Company Name | Corvus Pharmaceuticals, Inc. |
| CIK | 1626971 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (650) 900-4520 |